PAK5 and non-small cell lung carcinoma: The result showed that the PAK7 mutations were associated with the improved OS of immunotherapy, enhanced tumor immunogenicity, activated antitumor immunity, and alterations in tumor-related pathways, suggesting that PAK7 mutations might be used as an independent predictive biomarker for the NSCLC patients receiving ICI treatment.